Berson & Corrado Investment Advisors LLC Has $3.60 Million Position in Enzo Biochem, Inc. (ENZ)

Berson & Corrado Investment Advisors LLC increased its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 3.9% during the second quarter, Holdings Channel reports. The fund owned 326,101 shares of the medical research company’s stock after buying an additional 12,190 shares during the period. Enzo Biochem makes up approximately 2.0% of Berson & Corrado Investment Advisors LLC’s investment portfolio, making the stock its 16th largest position. Berson & Corrado Investment Advisors LLC’s holdings in Enzo Biochem were worth $3,600,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. American International Group Inc. increased its stake in Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock worth $204,000 after buying an additional 1,610 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock worth $1,728,000 after buying an additional 2,409 shares during the last quarter. Campbell & CO Investment Adviser LLC increased its stake in Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock worth $120,000 after buying an additional 2,812 shares during the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in Enzo Biochem by 0.9% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 831,354 shares of the medical research company’s stock worth $6,958,000 after buying an additional 7,401 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Enzo Biochem by 0.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,965,500 shares of the medical research company’s stock worth $13,641,000 after buying an additional 8,132 shares during the last quarter. Hedge funds and other institutional investors own 61.15% of the company’s stock.

Shares of Enzo Biochem, Inc. (ENZ) traded down 1.86% during mid-day trading on Monday, hitting $11.06. The company had a trading volume of 82,750 shares. Enzo Biochem, Inc. has a one year low of $4.88 and a one year high of $11.61. The company has a market capitalization of $513.26 million, a PE ratio of 15.51 and a beta of 0.98. The company’s 50-day moving average is $9.83 and its 200 day moving average is $8.04.

ILLEGAL ACTIVITY NOTICE: This story was originally published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.wkrb13.com/markets/2286113/berson-corrado-investment-advisors-llc-has-3-60-million-position-in-enzo-biochem-inc-enz.html.

Separately, Zacks Investment Research upgraded Enzo Biochem from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, June 20th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286113/berson-corrado-investment-advisors-llc-has-3-60-million-position-in-enzo-biochem-inc-enz.html

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.